An interventional study of ESM and Traqq in Irritable Bowel Syndrome, Inflammatory Bowel Diseases and Crohn Disease, sponsored by Maastricht University Medical Center. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center — 1 open to participants now, 2 under way, none of them phase 3. Irritable Bowel Syndrome · Maastricht University Medical Center.
Among the 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, and was the 13th registered.
1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.
Browse Irritable Bowel Syndrome studies →1 of the 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center is open now, in 1 country. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 18–75
By country, each count listing its studies:
Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 70 across 900 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 50 across the 12 interventional studies, 392 across the 2 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Apart from its use to provide insight in IBS disease courses and in clinical research, ESM can provide patients with feedback about individual triggers of their symptoms, and thereby function as part of a personalized therapeutic strategy. This is also true for IBD-IBS. Treatment strategies in IBS and IBD-IBS are largely based on reassurance, identification and elimination of triggering factors, and in more severe cases pharmaco- and psychotherapy. The ESM approach has the potential to increase therapeutic efficacy in IBS and IBD-IBS and will assist patients in disease self-management. The Traqq application can provide more detailed information about the dietary pattern of IBS and IBD-IBS patients. Traqq in combination with ESM will give an overview of abdominal pain and associated symptoms and psychosocial factors are exposed to during the day. The insight provided using ESM and Traqq may improve patient understanding of their personal symptom dynamics and triggers, as well as the physician's insight into the symptom patters of the specific patients, which may aid treatment choice and eventually improve the outcome of any treatment provided in daily clinical care.
This is an unicenter, prospective, proof-of-concept randomized controlled, non-blinded intervention study that focuses on two patient populations, with overlapping symptom patterns and treatment approaches, i.e. patients with IBS and IBD-IBS.
Following written informed consent, the eligibility screening is performed and instructions about the study procedures will be given. Hereafter, both groups will independently be randomized into i) an ESM/Traqq arm or ii) a standard care arm. The intervention group and the control group will complete the IBS-SSS, EO-5D-5L, GAD-7, PHQ-9, VSI, and MFl-20 as well as the Rome IV criteria for IBS and functional dyspepsia at baseline and the intervention group will complete thereafter the ESM and Traqq applications during the first week. After this week, the data will be analysed to identify associations between abdominal pain and psychosocial factors, diet or other GI associated symptoms. About two weeks later, participants will have their second visitation at the outpatient clinic with their treating physician. In the intervention group, but not the control group, the patient and the treating physician will receive the results of the personal data of the patients based on ESM and Traqq. The insight participants and their physicians get from this information, will help them to make changes in lifestyle factors that affect their symptoms or to choose a pharmacological or non-pharmacological treatment. However, the study protocol will not indicate which treatment choice should be made by the patient and their treating physicians. That choice will still be based on shared decision making, just as in the standard care arm, only with the additional data provided. Furthermore, if the patients are referred to a dietician, psychologist, or both, the digital data obtained in the intervention group can be used to personalize the therapy. After giving informed consent by the participant for the data of ESM and Traqq being sent to the dietician or psychologist they are referred to, the coordinating investigator will send the data digitally to the dietician or psychologist that is needed for the personalized treatment. Participants in the control arm will get a consultation with the gastroenterologist as usual after the same period of time as the intervention group get their consultation. The participants of the control group will be given treatment advice only based on this consultation, the PDSkeuzehulp by shared decision making, according to standard care. Twelve weeks after the second outpatient visit, independently of the chosen treatment approach, the participants in both study groups will be asked to complete IBS-SSS, EQ-5D-5L, GAD-7, PHO-9, VSI, MFI-20 and Rome IV criteria for IBS and functional dyspepsia for the second time to evaluate whether there is an effect on 1) reduction of abdominal pain and 2) quality of life, psychological aspects or fatigue of the participants due to the insight provided by ESM and Traqq.
After those twelve weeks, the coordinating investigator will contact the participants of the intervention group and control group by phone for the last time. Participants are asked what treatment they have gotten and what lifestyle modifications they have done to reduce abdominal pain. To improve compliance for completing the questionnaires by the control group, the participants in the control group will get the opportunity to use the ESM and Traqq applications after the study has been completed. This will not be part of this study but can be beneficial for those individuals who have not got any additional insight about their symptoms by getting the standard care.
The criteria were revised on the registry on Oct 8, 2026. See what changed
Inclusion criteria IBS patients
A diagnosis of IBS according to Rome IV criteria, as follows:
Inclusion criteria IBD patients
Patients with IBD diagnosed in accordance with current ECCO guidelines, with IBD- IBS and with chronic abdominal pain, as follows:
Exclusion criteria IBS patients
Exclusion criteria IBD patients
Use of ESM and Traqq for one week to get a personalised analysis of the abdominal pain and triggerfactors that can be used at the outpatient clinic visit to select an effective treatment option.
Device: ESM and Traqq
Will not be using ESM and Traqq, but will only get a standard outpatient clinic visit together with PDSkeuzehulp to make a decision for a treatment.
Two telephone applications: ESM is a psychosocial diary and Traqq is a food diary to measure abdominal pain as well as possible triggerfactors (i.e. diet, stress, anxiety)
Irritable Bowel Syndrome- Symptom Severity Score (IBS-SSS)
Change in IBS-SSS to see whether IBS symptoms are improved Scale 0-500 A higher score means worse outcome
Time frame: 12 weeks after outpatient clinic visit
General Anxiety Disorder-7 (GAD-7)
Change in GAD-7 to see whether complaints of anxiety are improved Scale 0-21 A higher score means worse outcome
Time frame: 12 weeks after outpatient clinic visit
Multidimensional Fatigue Inventory-20 (MFI-20)
Change in MFI-20 to see whether fatigue is improved Scale 20-100 A higher score means worse outcome
Time frame: 12 weeks after outpatient clinic visit
Patient Health Questionnaire-9 (PHQ-9)
Change in PHQ-9 to see whether complaints of depression are improved Scale 0-27 A higher score means worse outcome
Time frame: 12 weeks after outpatient clinic visit
Visceral Sensitivity Index (VSI)
Change in VSI to see whether complaints of GI related anxiety are improved Scale 0-75 A higher score means worse outcome
Time frame: 12 weeks after outpatient clinic visit
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L)
Change in EQ-5D-5L to see whether quality of life is improved Scale 5-25 A higher score means worse outcome
Time frame: 12 weeks after outpatient clinic visit
Plan to share: Yes — All research data will be saved as an SPSS file with all available metadata such as variables, value labels and definitions of missing data in accordance with the existing codebooks. In addition, the research data will be saved as csv files. After completion of the study, the data will be archived and the data will be stored in accordance with the required format of the relevant data archive.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Oct 2026, 41 months after the start.
Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 41 months is above that.
Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion May 2025 → Oct 2026 and completion May 2025 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →